With The Emergence Of DCTs, Do We Really Need A CTMS?

By Judson Chase, Principal Sales Consultant

During the COVID-19 pandemic, virtual physician-patient interactions allowed care while maintaining social distancing, inspiring the rise of decentralized clinical trials (DCTs) in the clinical trial industry. Given the popularity of decentralized trial designs, one question remains: will sponsors and CROs still require a CTMS?

In a hybrid trial, teams can utilize remote monitoring technologies and data collection methods to enable patients to participate in clinical trials from their homes. This provides several benefits, such as faster recruitment, reduction in patient burden, and larger patient populations. However, the current use of CTMS and electronic data capture (EDC) systems in traditional clinical trials doesn’t align with DCTs.

But that doesn’t mean CTMS can’t be integrated into a patient-centric clinical trial. The shift in trial design should push technology to keep pace with evolving study models, and the use of CTMS should grow as well. Discover how the integration of CTMS with DCTs can offer advantages such as real-time data collection, real-time patient and study team activity monitoring, and streamlined data access by all stakeholders.